Besides, eriodictyol can exert anti-cancer activity against nasopharyngeal cancer cells by blocking MEK/ERK signaling pathway, inducing cellular autophagy and suppressing cell migration and invasiveness. This evidence concerns the gene MAP2K7 and nasopharyngeal carcinoma.